1. Home
  2. SYRE

as 09-12-2025 10:19am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Founded: 2013 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 1.1B IPO Year: 2016
Target Price: $55.00 AVG Volume (30 days): 414.7K
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.85 EPS Growth: N/A
52 Week Low/High: $10.91 - $40.26 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

SYRE Daily Stock ML Predictions

Stock Insider Trading Activity of Spyre Therapeutics Inc. (SYRE)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Burrows Scott L SYRE Chief Financial Officer Sep 2 '25 Sell $16.26 18,428 $299,639.28 97,994

Share on Social Networks: